Medicus Pharma Ltd (MDCX)
NASDAQ (CM) NASDAQ (CM) Primary 
Medicus Pharma secures up to $22M in non-dilutive financing facility
Medicus Pharma (NASDAQ:MDCX) announced on Thursday that it has entered into a definitive financing agreement with an institutional investor for an up to $22 million structured, non-dilutive financing facility aimed at supporting its clinical development programs and extending its cash runway. The biotech and life sciences company said the financing is expected to increase its pro forma cash position to about $30 million and provide projected operating liquidity for more than 24 months.
Medicus Pharma sees catalyst-rich year ahead as SkinJect and Teverelix progress
Medicus Pharma (NASDAQ:MDCX) reported first quarter 2026 financial results on Thursday, highlighting progress across its SkinJect and Teverelix clinical programs while continuing efforts to strengthen its financing position. The biotech company said it recently reported positive expanded Phase 2 data for its SkinJect Doxorubicin Microneedle Array treatment for nodular basal cell carcinoma, including what it described as registrational-grade clearance rates in the 200-microgram treatment cohort.
Medicus Pharma highlights positive dose-response in updated skin cancer trial results
Medicus Pharma (NASDAQ:MDCX) has reported additional results from a pre-specified expanded dataset analysis of its Phase 2 SKNJCT-003 trial, showing a positive dose-response relationship for its Doxorubicin Microneedle Array (D-MNA) in treating nodular basal cell carcinoma (BCC). The analysis builds on previously disclosed topline results and incorporates biological, histologic, and safety data from a refined group of 69 patients whose diagnoses met the study's intended inclusion criteria.
Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome
Medicus Pharma (NASDAQ:MDCX) said on Monday its chief executive and senior leadership team met with US lawmakers on Capitol Hill to seek support for regulatory and policy measures aimed at advancing its SkinJect therapy for patients with Gorlin syndrome, a rare inherited condition linked to recurrent skin cancers. The biotech company said the discussions focused on securing orphan drug designation for SkinJect for Gorlin syndrome, registrational investigational new drug approval for affected patients, and support for the rare disease pediatric FDA voucher program.
Medicus Pharma seeks orphan drug status for SkinJect in rare skin cancer disorder
Medicus Pharma (NASDAQ:MDCX) said on Friday it has submitted an application to the US Food and Drug Administration seeking orphan drug designation for its SkinJect therapy to treat basal cell carcinoma in patients with Gorlin Syndrome, a rare genetic condition marked by recurring skin cancers. The company said the filing expands its SkinJect program into an area of high unmet medical need, where treatment options are limited and often rely on repeated surgical procedures that can lead to cumulative physical and psychological burden.
Medicus Pharma to present new Teverelix data at upcoming endocrinology meeting
Medicus Pharma (NASDAQ:MDCX) announced plans to present new early-stage clinical data on its investigational drug candidate, Teverelix, at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 in Las Vegas later this month. The company said the presentation will include results from two Phase 1 studies evaluating Teverelix, a long-acting gonadotropin-releasing hormone (GnRH) antagonist being developed for hormone-related conditions.
Medicus Pharma submits optimized Phase 2 Teverelix trial protocol to FDA
Medicus Pharma (NASDAQ:MDCX) announced on Monday that it has submitted an optimized Phase 2 clinical study protocol to the US Food and Drug Administration (FDA) for Teverelix, an investigational GnRH antagonist. The study is designed to evaluate the drug's effectiveness in preventing recurrent acute urinary retention (AURr) in men with benign prostatic hyperplasia (BPH) as part of an existing open Investigational New Drug application.
Medicus Pharma SkinJect Phase 2 study data endorsed by independent expert - ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week outlined further progress in its Skinject program following the release of Phase 2 topline data, alongside independent validation from a leading dermatology expert. The company's CEO Raza Bokhari said Medicus Pharma is advancing a novel, noninvasive treatment using patent-protected microneedle arrays designed to treat non-melanoma skin diseases, particularly basal cell carcinoma.
Medicus Pharma eyes registrational study for SkinJect after positive Phase 2 data
Medicus Pharma (NASDAQ:MDCX) said on Wednesday its Phase 2 study of SkinJect (SKNJCT-003), a doxorubicin-containing microneedle array for nodular basal cell carcinoma (BCC), showed clinically meaningful activity, supporting plans to advance the therapy toward registrational development. “We believe the positive topline results from 200 ug cohort at day 57, support the therapeutic value of SkinJect and establishes the best path forward towards registrational study,” said Dr. Raza Bokhari, executive chairman and CEO of Medicus.
Medicus Pharma highlights independent support for Phase 2 SkinJect results
Medicus Pharma (NASDAQ:MDCX) announced that an independent assessment of its Phase 2 SkinJect study supports the clinical relevance of the data and continued development of the experimental therapy for non-melanoma skin cancer. The evaluation was provided by Dr Babar Rao, principal investigator of the SKNJCT-003 trial, who described the dataset as “clinically meaningful” and supportive of further trials and regulatory engagement.
Medicus Pharma advances SkinJect, Teverelix programs, eyes catalyst-rich 2026
Medicus Pharma (NASDAQ:MDCX) said on Thursday it is entering a “catalyst-rich” 2026 after reporting annual results and highlighting progress across its SkinJect and Teverelix programs, alongside expansion into precision medicine and AI-enabled clinical development. The clinical-stage biotech said 2025 marked a pivotal year, driven by completion of a Phase 2 study for SkinJect and efforts to broaden its pipeline into rare diseases and women's health.
Medicus Pharma CEO discusses promising Phase 2 SkinJect results - ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week highlighted encouraging data from its Phase 2 clinical trial evaluating SkinJect, a non-invasive treatment designed to address basal cell carcinoma, the most common form of skin cancer. Speaking to Proactive, chief executive Raza Bokhari said the latest dataset suggests the company's microneedle-based therapy could significantly reduce the need for surgical intervention in many patients.
